Hypereosinophilic Syndrome disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

HES MCID: HYP098 MIFTS: 66	Hypereosinophilic Syndrome (HES) Categories: Blood diseases, Cancer diseases, Immune diseases, Neuronal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Hypereosinophilic Syndrome

MalaCards integrated aliases for Hypereosinophilic Syndrome:

Name: Hypereosinophilic Syndrome ¹¹ ¹⁹ ⁵⁸ ⁷⁵ ⁵³ ¹⁴ ¹⁶ ⁷¹

Eosinophilia ¹¹ ⁷⁵ ²⁸ ⁵³ ⁵ ⁴³ ¹⁴ ⁷¹ ³¹ ³³

Hes ¹⁹ ⁵⁸ ⁴⁷

Disseminated Eosinophilic Collagen Disease ⁷¹

Disorders with Increased Eosinophil Counts ³³

Hypereosinophilic Syndrome, Idiopathic ¹⁹

Idiopathic Hypereosinophilic Syndrome ⁷¹

Eosinophilic Leukocytosis ¹¹

Eosinophilic Disorder ⁷¹

Characteristics:

Prevelance:

<1/1000000 (United States, Europe) 1-9/100000 (Europe, United States) ⁵⁸

Age Of Onset:

All ages ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Immune diseases Blood diseases Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

Other diseases of blood and blood-forming organs

Other disorders of white blood cells

Eosinophilia

Neoplasms

Neoplasms of uncertain or unknown behaviour

Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue

Chronic eosinophilic leukaemia [hypereosinophilic syndrome]

ICD11: ³³

Diseases of the immune system

Immune system disorders involving white cell lineages

Eosinophilia

Eosinophilia, unspecified

Orphanet: ⁵⁸

Rare haematological diseases

External Ids:

Disease Ontology ¹¹ DOID:999

ICD9CM ³⁴ 288.3

MeSH ⁴³ D004802

SNOMED-CT ⁶⁸ 418928000

ICD10 ³¹ D72.1

MESH via Orphanet ⁴⁴ D017681

ICD10 via Orphanet ³² D47.5

UMLS via Orphanet ⁷² C1540912

Orphanet ⁵⁸ ORPHA168956

EFO ¹⁶ EFO_1001467

ICD11 ³³ 726177562 726177562/unspecified

UMLS ⁷¹ C0014457 C0206141 C0263662 more

Sources

Summaries for Hypereosinophilic Syndrome

GARD: ¹⁹ Hypereosinophilic syndrome (HES) refers to a rare group of conditions that are associated with persistent eosinophilia with evidence of organ involvement. Signs and symptoms vary significantly based on which parts of the body are affected. Although any organ system can be involved in HES, the heart, central nervous system, skin, and respiratory tract are the most commonly affected. The condition was originally thought to be "idiopathic" or of unknown cause. However, recent advances in diagnostic testing have allowed a cause to be identified in approximately a quarter of cases.

MalaCards based summary: Hypereosinophilic Syndrome, also known as eosinophilia, is related to hypereosinophilic syndrome, idiopathic and primary hypereosinophilic syndrome, and has symptoms including nausea and vomiting, constipation and angina pectoris. An important gene associated with Hypereosinophilic Syndrome is FIP1L1 (Factor Interacting With PAPOLA And CPSF1), and among its related pathways/superpathways are Innate Immune System and Signal Transduction. The drugs Prednisone and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, heart and bone, and related phenotypes are Decreased viability and Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435)

Orphanet: ⁵⁸ Hypereosinophilic syndrome (HES) constitutes a rare and heterogeneous group of disorders, defined as persistent and marked blood eosinophilia and/or tissue eosinophilia associated with a wide range of clinical manifestations reflecting eosinophil-induced tissue/organ damage.

Disease Ontology: ¹¹ A leukocyte disease that is characterized by high numbers of eosinophils which over time enter various tissues, eventually damaging organs.

Wikipedia ⁷⁵ Hypereosinophilic syndrome: Hypereosinophilic syndrome is a disease characterized by a persistently elevated eosinophil count (≥... more...

Eosinophilia: Eosinophilia is a condition in which the eosinophil count in the peripheral blood exceeds 5×108/L... more...

Sources

Related Diseases for Hypereosinophilic Syndrome

Diseases in the Hypereosinophilic Syndrome family:

Secondary Hypereosinophilic Syndrome

Primary Hypereosinophilic Syndrome

Diseases related to Hypereosinophilic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1527)

#	Related Disease	Score	Top Affiliating Genes
1	hypereosinophilic syndrome, idiopathic	33.1	PDGFRB PDGFRA KIT IL5 IL3 FIP1L1
2	primary hypereosinophilic syndrome	32.9	PDGFRB PDGFRA FIP1L1 FGFR1
3	loeffler syndrome	32.5	PRG2 IL5 FIP1L1
4	myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1	32.4	PDGFRB PDGFRA FIP1L1 FGFR1
5	paragonimiasis	32.1	RNASE3 IL5 IGHE
6	loeffler endocarditis	32.1	RNASE3 PRG2 PDGFRA IL5 IL3 FIP1L1
7	endomyocardial fibrosis	32.0	RNASE3 PRG2 PDGFRB PDGFRA IL5 FIP1L1
8	aggressive systemic mastocytosis	31.8	PDGFRB PDGFRA KIT JAK2 FIP1L1 ABL1
9	myeloid and lymphoid neoplasms associated with pdgfra rearrangement	31.8	PDGFRB PDGFRA KIT JAK2 FIP1L1 FGFR1
10	pulmonary eosinophilia	31.8	RNASE3 PRG2 IL5 EPX CXCL8 CSF2
11	myeloid and lymphoid neoplasms associated with fgfr1 abnormalities	31.7	IL3 IL2RA FGFR1
12	neutropenia, severe congenital, 3, autosomal recessive	31.7	IL3 CSF2
13	restrictive cardiomyopathy	31.3	RNASE3 PDGFRA FIP1L1 EPX
14	chronic eosinophilic leukemia	31.3	PDGFRB PDGFRA KIT JAK2 IL5 IL3
15	strongyloidiasis	31.1	IL5 IGHE CCL11
16	exanthem	31.1	KIT IFNA1 CXCL8 CSF2
17	neutrophilia, hereditary	31.0	JAK2 IL3 CSF2
18	aspergillosis	31.0	IL5 EPX CXCL8 CSF2
19	peripheral t-cell lymphoma	31.0	PDGFRB PDGFRA IL2RA ABL1
20	churg-strauss syndrome	31.0	RNASE3 PRG2 IL5 IL3 IL2RA CXCL8
21	peripheral nervous system disease	30.9	KIT JAK2 IFNA1 CXCL8 CSF2
22	budd-chiari syndrome	30.9	PDGFRA JAK2 FIP1L1
23	mastocytosis, cutaneous	30.9	PDGFRA KIT IL3 FIP1L1
24	systemic mastocytosis	30.8	PDGFRB PDGFRA KIT JAK2 IL2RA FIP1L1
25	mastocytosis	30.8	PDGFRB PDGFRA KIT JAK2 IL3 IL2RA
26	leukemia, acute lymphoblastic	30.8	KIT JAK2 IL3 CSF2 ABL1
27	toxocariasis	30.8	RNASE3 IL5 IGHE FIP1L1
28	diarrhea	30.8	IL5 IL3 IFNA1 CXCL8
29	leukemia	30.7	PDGFRB KIT JAK2 IL3 FGFR1 CSF2
30	eosinophilic gastroenteritis	30.7	RNASE3 IL5 IL3 IGHE FIP1L1 EPX
31	angiosarcoma	30.7	PDGFRB PDGFRA KIT ABL1
32	granulocytopenia	30.7	IL3 CSF2
33	eosinophilic pneumonia	30.7	RNASE3 IL5 IL3 FIP1L1 CXCL8 CSF2
34	myeloproliferative neoplasm	30.7	ZBTB20 PDGFRB PDGFRA KIT JAK2 IL3
35	dermatitis	30.7	RNASE3 IL5 IGHE IGES CXCL8 CCL11
36	proteasome-associated autoinflammatory syndrome 1	30.7	RNASE3 IL5 IGHE IFNA1 CXCL8 CCL11
37	urticaria	30.7	RNASE3 PRG2 KIT IL5 IL3 IGHE
38	pemphigoid	30.7	RNASE3 IL5 CXCL8 CCL11
39	myelofibrosis	30.6	PDGFRB KIT JAK2 IL3 IL2RA IFNA1
40	kimura disease	30.6	RNASE3 IL5 IGHE IGES
41	primary cutaneous t-cell non-hodgkin lymphoma	30.6	IL5 IL2RA IFNA1
42	leukemia, chronic myeloid	30.6	PDGFRB PDGFRA KIT JAK2 IL3 IFNA1
43	eosinophilic gastritis	30.6	IL5 FIP1L1 EPX CCL11
44	dermatographia	30.6	PRG2 IGHE
45	trichinosis	30.6	IL5 IL3 CCL11
46	cellulitis	30.6	RNASE3 IL5 IGES CXCL8 CSF2
47	acute leukemia	30.6	KIT JAK2 IL3 CSF2
48	childhood-onset asthma	30.6	RNASE3 IL5 IGHE IGES EPX CCL11
49	bronchiolitis	30.6	RNASE3 IL5 IFNA1 CXCL8 CSF2 CCL11
50	bullous pemphigoid	30.6	RNASE3 IL5 IGHE CXCL8 CCL11

Comorbidity relations with Hypereosinophilic Syndrome via Phenotypic Disease Network (PDN):

Acute Cystitis	Bronchitis
Deficiency Anemia	Heart Disease
Hypertension, Essential

Graphical network of the top 20 diseases related to Hypereosinophilic Syndrome:

Sources

Symptoms & Phenotypes for Hypereosinophilic Syndrome

UMLS symptoms related to Hypereosinophilic Syndrome:

nausea and vomiting; constipation; angina pectoris; abdominal pain; myalgia; chest pain; pruritus; diarrhea; edema; snoring; dyspepsia; icterus; coughing; heartburn; gastrointestinal gas

GenomeRNAi Phenotypes related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

²⁵ (show all 16)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00173-A	9.98	PDGFRA
2	Decreased viability	GR00221-A-1	9.98	ABL1 FGFR1 KIT PDGFRA PDGFRB
3	Decreased viability	GR00221-A-2	9.98	ABL1 FGFR1
4	Decreased viability	GR00221-A-3	9.98	ABL1 PDGFRA PDGFRB
5	Decreased viability	GR00221-A-4	9.98	PDGFRA PDGFRB
6	Decreased viability	GR00249-S	9.98	PDGFRA
7	Decreased viability	GR00301-A	9.98	KIT
8	Decreased viability	GR00342-S-1	9.98	ABL1 PDGFRB
9	Decreased viability	GR00342-S-2	9.98	ABL1
10	Decreased viability	GR00342-S-3	9.98	ABL1
11	Decreased viability	GR00386-A-1	9.98	FGFR1
12	Decreased viability	GR00402-S-2	9.98	PDGFRA
13	Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435)	GR00104-A-0	9.46	CSF2 CXCL8 IL2RA PDGFRB
14	Decreased substrate adherent cell growth	GR00193-A-1	9.1	KIT
15	Decreased substrate adherent cell growth	GR00193-A-2	9.1	ABL1 KIT
16	Decreased substrate adherent cell growth	GR00193-A-4	9.1	ABL1 FGFR1 KIT

MGI Mouse Phenotypes related to Hypereosinophilic Syndrome:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	immune system	MP:0005387	10.06	ABL1 CCL11 CSF2 EPX FGFR1 IFNA1
2	respiratory system	MP:0005388	9.7	ABL1 CCL11 CSF2 IFNA1 IL2RA IL3
3	hematopoietic system	MP:0005397	9.53	ABL1 CCL11 CSF2 EPX FGFR1 IFNA1

Sources

Drugs & Therapeutics for Hypereosinophilic Syndrome

Drugs for Hypereosinophilic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Prednisone

Approved, Vet_approved

Phase 4

53-03-2

5865

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Prednisolone phosphate

Approved, Vet_approved

Phase 4

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 4

52-21-1

Prednisolone

Approved, Vet_approved

Phase 4

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 4

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 4

83-43-2

4159 6741

Azithromycin

Approved

Phase 4

83905-01-5

447043

Salbutamol

Approved, Vet_approved

Phase 4

18559-94-9

2083

Budesonide

Approved

Phase 4

51333-22-3

5281004 40000 63006

Prednisolone hemisuccinate

Experimental

Phase 4

2920-86-7

4897

Protective Agents

Phase 4

Anti-Allergic Agents

Phase 4

Neuroprotective Agents

Phase 4

Antiemetics

Phase 4

Gastrointestinal Agents

Phase 4

Antineoplastic Agents, Hormonal

Phase 4

Methylprednisolone Acetate

Phase 4

584547

Hormones

Phase 4

Hormone Antagonists

Phase 4

glucocorticoids

Phase 4

Anti-Inflammatory Agents

Phase 4

Neurotransmitter Agents

Phase 4

Bronchodilator Agents

Phase 4

Adrenergic beta-Agonists

Phase 4

Adrenergic Agonists

Phase 4

Adrenergic Agents

Phase 4

Tocolytic Agents

Phase 4

Budesonide, Formoterol Fumarate Drug Combination

Phase 4

Formoterol Fumarate

Phase 4

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Asparaginase Escherichia coli

Approved, Investigational

Phase 3

9015-68-3

Tioguanine

Approved

Phase 3

154-42-7

2723601

Daunorubicin

Approved

Phase 3

20830-81-3

30323

Busulfan

Approved, Investigational

Phase 3

55-98-1

2478

Aldesleukin

Approved

Phase 3

110942-02-4

Benralizumab

Approved, Investigational

Phase 3

1044511-01-4

Ketotifen

Approved

Phase 3

34580-14-8, 34580-13-7

3827

Histamine

Approved, Investigational

Phase 3

51-45-6

774

Reslizumab

Approved, Investigational

Phase 3

241473-69-8

Aspartic acid

Approved, Nutraceutical

Phase 3

56-84-8

5960

Alkylating Agents

Phase 3

Antineoplastic Agents, Alkylating

Phase 3

N-Methylaspartate

Phase 3

Anti-Retroviral Agents

Phase 3

Interleukin-2

Phase 3

Anti-HIV Agents

Phase 3

Analgesics, Non-Narcotic

Phase 3

Calcium, Dietary

Phase 3

Interventional clinical trials:

(show top 50) (show all 207)

#	Name	Status	NCT ID	Phase	Drugs
1	How to "Choosebetweenamab" for Severe Asthma, Comparing Treatment With Mepolizumab and Omalizumab for Patients With Severe Allergic and Eosinophilic Asthma.	Unknown status	NCT04585997	Phase 4	Mepolizumab;Omalizumab
2	A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil	Unknown status	NCT04228588	Phase 4	Mepolizumab 100 MG [Nucala]
3	Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma	Unknown status	NCT03652376	Phase 4	Benralizumab
4	Assessment of Glucocorticoid Responsiveness and Mechanisms of Resistance in Hypereosinophilic Syndromes	Completed	NCT01524536	Phase 4	prednisone
5	Phase 4, Randomized Study of Three Months-prednisolone Therapy in the Treatment of Chronic Eosinophilic Pneumonia	Completed	NCT00632554	Phase 4	prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months
6	A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)	Completed	NCT02654145	Phase 4	Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
7	Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma and Persistent Sputum Eosinophilia Despite Standard Dose Therapy	Recruiting	NCT04710134	Phase 4
8	BURAN: Effects of Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging Parameters	Recruiting	NCT05552508	Phase 4
9	A Phase 4, Open-label, Single Arm, 24-week, Phase 4 Study to Evaluate the Safety and Efficacy of Mepolizumab 100 mg SC Administered Every 4 Weeks in Indian Participants Aged >=18 Years With Severe Eosinophilic Asthma Requiring Oral Corticosteroid Treatment to Maintain Asthma Control (PRISM)	Recruiting	NCT04276233	Phase 4	Prednisone/ Prednisolone;Salbutamol
10	Effects of Azithromycin Treatment on Anti-viral Immunity in Patients With Asthma and COPD - A Randomized Double-blind, Placebo-controlled Trial	Recruiting	NCT04319705	Phase 4	Azithromycin;Placebo oral tablet
11	Predictive Signature of Benralizumab Response	Recruiting	NCT04565483	Phase 4	Benralizumab Prefilled Syringe
12	SHAMAL: A Multicentre, Randomised, Open-Label, Parallel-Group, Active-Controlled, Phase IV Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab	Active, not recruiting	NCT04159519	Phase 4	Symbicort®;Fasenra®;Ventolin®
13	Route of Administration of Anti-IL5 Monoclonal Antibody in Prednisone-dependent Eosinophilic Asthma	Completed	NCT02559791	Phase 2, Phase 3	Placebo
14	A Three-part,Multicenter Study,With a Randomized,Double-blind,Placebo Controlled,Withdrawal Design in Part II to Assess Efficacy,Safety,and Tolerability of ACZ885(Anti-interleukin-1beta Monoclonal Antibody)in Patients With Muckle-Wells Syndrome	Completed	NCT00465985	Phase 3	ACZ885;Placebo
15	An Open-label Study to Evaluate the Pharmacokinetics and Pharmacodynamics and Long-term Safety of Benralizumab Administered Subcutaneously in Children With Severe Eosinophilic Asthma	Completed	NCT04305405	Phase 3	Benralizumab
16	A Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Compare Cessation Versus Continuation of Long-term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma (201810)	Completed	NCT02555371	Phase 3	Placebo
17	An Open-label, Long-term Safety and Efficacy Study of ACZ885 (Anti-interleukin-1β Monoclonal Antibody) Administered for at Least 6 Months in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease	Completed	NCT00685373	Phase 3	Canakinumab (ACZ885)
18	A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Eosinophilic Asthma on Markers of Asthma Control	Completed	NCT02281318	Phase 3	Placebo;SOC
19	An Open-label, Efficacy and Safety Study of Canakinumab (Anti-interleukin-1β Monoclonal Antibody) Administered for 6 Months (24 Weeks) in Japanese Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease, Followed by an Extension Phase to Provide Canakinumab to Study Patients Until it is Approved and Marketed in Japan	Completed	NCT00991146	Phase 3	canakinumab
20	A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma	Completed	NCT01270464	Phase 3	Reslizumab;Placebo
21	An Open-label Extension Study to Assess Efficacy, Safety and Tolerability of Canakinumab and the Efficacy and Safety of Childhood Vaccinations in Patients With Cryopyrin Associated Periodic Syndromes (CAPS)	Completed	NCT01576367	Phase 3
22	A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma	Completed	NCT01287039	Phase 3	Reslizumab;Placebo
23	A Randomized, Double-Blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Benralizumab (Anti-IL5RA) in Subjects With Eosinophilic Gastritis	Completed	NCT03473977	Phase 2, Phase 3
24	A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma	Completed	NCT01285323	Phase 3	Reslizumab;Placebo
25	A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) Treatment in Patients With Moderate to Severe Asthma	Completed	NCT01508936	Phase 3	Reslizumab;Placebo
26	A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS)	Completed	NCT01302860	Phase 3	ACZ885
27	A Multi-centre, Open-label Extension, Safety Study to Describe the Long-term Clinical Experience of Mepolizumab in Participants With Hypereosinophilic Syndrome (HES) From Study 200622	Completed	NCT03306043	Phase 3	Mepolizumab
28	Study 200622: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Adolescent and Adult Subjects With Severe Hypereosinophilic Syndrome	Completed	NCT02836496	Phase 3	Mepolizumab 300 mg;Placebo matching mepolizumab;Active OCS capsules (5 mg prednisolone or prednisone);Placebo matching OCS capsules
29	A Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- Sparing Effects of Mepolizumab in Subjects With Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of Subjects With HES	Completed	NCT00086658	Phase 3	mepolizumab
30	INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation	Completed	NCT00799461	Phase 3
31	The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years	Completed	NCT00369317	Phase 3	asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
32	Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML < 60 Years	Completed	NCT00006363	Phase 3	cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
33	A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation	Completed	NCT01305200	Phase 3	supersaturated calcium phosphate rinse
34	A Randomised Controlled Trial of Mepolizumab Initiated Following Admission to Hospital for a Severe Exacerbation of Eosinophilic COPD	Recruiting	NCT04075331	Phase 2, Phase 3	Mepolizumab;Placebo
35	Double-blind, Placebo-controlled, Cross-over Trial of Ketotifen in Children and Adolescents With Functional Dyspepsia in Association With Duodenal Eosinophilia	Recruiting	NCT02484248	Phase 3	Ketotifen;Placebo
36	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Subjects With Eosinophilic Gastroenteritis	Recruiting	NCT05214768	Phase 3	CC-93538;Placebo
37	A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled 3-Part Phase 3 Study to Demonstrate the Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)	Recruiting	NCT05251909	Phase 3
38	A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of Subcutaneous AK002 in Subjects With Moderate to Severe Eosinophilic Gastritis and/or Eosinophilic Duodenitis	Recruiting	NCT05152563	Phase 3	AK002
39	Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies	Recruiting	NCT03470311	Phase 3
40	A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-week Phase 3 Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)	Recruiting	NCT04191304	Phase 3
41	A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES)	Recruiting	NCT05334368	Phase 3	Depemokimab
42	A Phase 3, 52-week, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Mepolizumab SC in Participants Aged 6 to 17 Years With Hypereosinophilic Syndrome	Recruiting	NCT04965636	Phase 3	Mepolizumab
43	A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Benralizumab (MEDI-563) in Reducing Eosinophilia in Subjects With Hypereosinophilic Syndrome (HES)	Active, not recruiting	NCT02130882	Phase 2, Phase 3	benralizumab
44	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AK002 in Patients With Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)	Active, not recruiting	NCT04322604	Phase 3	lirentelimab (AK002)
45	A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Efficacy and Safety of AK002 in Patients That Were Previously Enrolled in AK002-016 or AK002-012 Studies and Have Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)	Enrolling by invitation	NCT04620811	Phase 3	lirentelimab
46	Treatment of DRESS (Drug Reaction With Eosinophilia and Systemic Symptoms) With Tegeline®	Terminated	NCT00505648	Phase 3	Tegeline®
47	An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma	Terminated	NCT03052725	Phase 3	reslizumab
48	A Randomized, Double-blind, Placebo-controlled, Mono-center Study to Evaluate the Effects of Mepolizumab on Airway Physiology in Patients With Eosinophilic Asthma: the MEMORY Study	Terminated	NCT02594332	Phase 3	Mepolizumab;Placebo
49	A 52 Week, Randomised, Double Blind, Multinational, Multicentre, 4-arm Parallel Group Trial to Assess the Efficacy and Safety of 3 Doses of CHF 6532 Compared to Placebo on Top of Standard of Care in Patients With Uncontrolled Severe Eosinophilic Asthma	Terminated	NCT04049175	Phase 3	Treatment A;Treatment B;Treatment C;Treatment D
50	An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients With Eosinophilic Asthma Who Completed a Prior Teva-Sponsored Study in Eosinophilic Asthma	Terminated	NCT01290887	Phase 3	Reslizumab

Search NIH Clinical Center for Hypereosinophilic Syndrome

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

hydroxyurea

imatinib

Imatinib mesylate

Interferon Alfa-2a

Interferon Alfa-2b

INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED

interferon alfacon-1

Interferon gamma-1b

Interferons

peginterferon alfa-2a

peginterferon alfa-2b

Recombinant interferon beta-1a

Recombinant interferon beta-1b

Cochrane evidence based reviews: eosinophilia

Sources

Genetic Tests for Hypereosinophilic Syndrome

Genetic tests related to Hypereosinophilic Syndrome:

#	Genetic test	Affiliating Genes
1	Eosinophilia ²⁸

Sources

Anatomical Context for Hypereosinophilic Syndrome

Organs/tissues related to Hypereosinophilic Syndrome:

MalaCards : Bone Marrow, Heart, Bone, Myeloid, Skin, Lung, Liver

Sources

Publications for Hypereosinophilic Syndrome

Articles related to Hypereosinophilic Syndrome:

(show top 50) (show all 23052)

#	Title	Authors	PMID	Year
1	Delayed-type asthmatic response to bronchial challenge with allergen, I: clinical features. ⁵³ ⁶²	Pelikan Z	20486329	2010
2	Early phase resolution of mucosal eosinophilic inflammation in allergic rhinitis. ⁵³ ⁶²	Uller L...Persson CG	20459697	2010
3	Thrombotic storm in Kimura disease. ⁵³ ⁶²	Liu H...Lottenberg R	19468829	2010
4	IL-13 Gene Polymorphisms are Associated With Rhinosinusitis and Eosinophilic Inflammation in Aspirin Intolerant Asthma. ⁵³ ⁶²	Palikhe NS...Park HS	20358028	2010
5	Airway wall expression of OX40/OX40L and interleukin-4 in asthma. ⁵³ ⁶²	Siddiqui S...Brightling C	20139223	2010
6	Allergen-induced, eotaxin-rich, proangiogenic bone marrow progenitors: a blood-borne cellular envoy for lung eosinophilia. ⁵³ ⁶²	Asosingh K...Erzurum SC	20227754	2010
7	Critical role of the platelet-derived growth factor receptor (PDGFR) beta transmembrane domain in the TEL-PDGFRbeta cytosolic oncoprotein. ⁵³ ⁶²	Toffalini F...Demoulin JB	20164181	2010
8	Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. ⁵³ ⁶²	Tefferi A...Pardanani A	20053713	2010
9	Vernal keratoconjunctivitis--a rare but serious comorbidity of allergic rhinitis and eustachian tube dysfunction. ⁵³ ⁶²	Bozkurt MK...Reisli I	19900723	2010
10	Hyper-IgE syndrome with STAT3 mutation: a case report in Mainland China. ⁵³ ⁶²	Xie L...Chen L	20490271	2010
11	Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies. ⁵³ ⁶²	Mapletoft JW...van Drunen Littel-van den Hurk S	19864487	2010
12	A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report. ⁵³ ⁶²	Rodzaj M...Zdunczyk A	20010473	2009
13	Effects of omalizumab on markers of inflammation in patients with allergic asthma. ⁵³ ⁶²	Holgate S...Jimenez P	19839977	2009
14	Concomitant occurrence of kimura disease and mycosis fungoides in a Lebanese woman: significance and response to rituximab. ⁵³ ⁶²	Ghosn S...Taher A	19786854	2009
15	Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. ⁵³ ⁶²	Tefferi A...Vardiman JW	19806146	2009
16	Kimura's disease presenting with a giant suspensory tumor and associated with membranoproliferative glomerulonephritis. ⁵³ ⁶²	Kabashima R...Tokura Y	19620037	2009
17	A low dose of Mycoplasma pneumoniae infection enhances an established allergic inflammation in mice: the role of the prostaglandin E2 pathway. ⁵³ ⁶²	Wu Q...Chu HW	19552640	2009
18	Triptolide abrogates oncogene FIP1L1-PDGFRalpha addiction and induces apoptosis in hypereosinophilic syndrome. ⁵³ ⁶²	Jin Y...Pan J	19671059	2009
19	Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. ⁵³ ⁶²	Paruchuri S...Boyce JA	19822647	2009
20	Recurrent giant chalazia in hyperimmunoglobulin E (Job's) syndrome. ⁵³ ⁶²	Patteri P...Pinna A	18528638	2009
21	Is serum total IgE levels a good predictor of allergies in children? ⁵³ ⁶²	Satwani H...Hassan A	19813686	2009
22	T-helper type 2-driven inflammation defines major subphenotypes of asthma. ⁵³ ⁶²	Woodruff PG...Fahy JV	19483109	2009
23	Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification. ⁵³ ⁶²	Hebeda KM...Fend F	20309429	2009
24	Innate cells and T helper 2 cell immunity in airway inflammation. ⁵³ ⁶²	Barrett NA...Austen KF	19766085	2009
25	Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia. ⁵³ ⁶²	Lierman E...Cools J	19761433	2009
26	Formulation of bovine respiratory syncytial virus fusion protein with CpG oligodeoxynucleotide, cationic host defence peptide and polyphosphazene enhances humoral and cellular responses and induces a protective type 1 immune response in mice. ⁵³ ⁶²	Kovacs-Nolan J...van Drunen Littel-van den Hurk S	19386785	2009
27	Similar colds in subjects with allergic asthma and nonatopic subjects after inoculation with rhinovirus-16. ⁵³ ⁶²	DeMore JP...Gern JE	19596142	2009
28	Blockade of CCR4 in a humanized model of asthma reveals a critical role for DC-derived CCL17 and CCL22 in attracting Th2 cells and inducing airway inflammation. ⁵³ ⁶²	Perros F...Hammad H	19630858	2009
29	Production of interleukin-10 in asthmatic children after Beta-1-3-glucan. ⁵³ ⁶²	Sarinho E...Rizzo JA	19912977	2009
30	Clinical significance of eosinophilic cationic protein levels in nasal secretions of patients with nasal polyposis. ⁵³ ⁶²	Sun DI...Kang JM	19034473	2009
31	Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. ⁵³ ⁶²	Jain N...Verstovsek S	19013640	2009
32	A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. ⁵³ ⁶²	Salemi S...Simon HU	19210352	2009
33	Pathogenesis of Churg-Strauss syndrome: recent insights. ⁵³ ⁶²	Zwerina J...Schett G	19811306	2009
34	Eosinophilia-associated muscle disorders: an immunohistological study with tissue localisation of major basic protein in distinct clinicopathological forms. ⁵³ ⁶²	Cantarini L...Galeazzi M	19139036	2009
35	A scleroderma-like cutaneous syndrome associated with a marked Th2-type immune response occurring after a prosthetic joint implant. ⁵³ ⁶²	Romano C...Lucivero G	19300283	2009
36	IL-25: a key requirement for the regulation of type-2 immunity. ⁵³ ⁶²	Barlow JL...McKenzie AN	19449446	2009
37	VCAM-1 and eosinophilia in diffuse sino-nasal polyps. ⁵³ ⁶²	Eweiss A...Hammad Z	18642014	2009
38	Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. ⁵³ ⁶²	Tefferi A	19175693	2009
39	Reciprocal regulation of iNOS and PARP-1 during allergen-induced eosinophilia. ⁵³ ⁶²	Naura AS...Boulares AH	18829681	2009
40	Evidence that 13-14 di-hydro, 15-keto prostaglandin D(2)-induced airway eosinophilia in guinea-pigs is independent of interleukin-5. ⁵³ ⁶²	Whelan CJ	19184361	2009
41	Kimura's disease in a young Balkan male. ⁵³ ⁶²	Milentijevi MJ...Petrovic A	19195268	2009
42	Th2 cells as targets for therapeutic intervention in allergic bronchial asthma. ⁵³ ⁶²	Wegmann M	19099351	2009
43	Thrombosis of temporal artery and renal vein in Kimura-disease-related nephrotic syndrome. ⁵³ ⁶²	Danis R...Kilinc I	18066701	2009
44	Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD. ⁵³ ⁶²	Bafadhel M...Brightling CE	19478474	2009
45	Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. ⁵³ ⁶²	Gotlib J...Cools J	18843283	2008
46	Immunosuppression of TH2 responses in Trichinella spiralis infection by Helicobacter pylori neutrophil-activating protein. ⁵³ ⁶²	Del Prete G...Bruschi F	18804852	2008
47	TARC and IL-5 expression correlates with tissue eosinophilia in peripheral T-cell lymphomas. ⁵³ ⁶²	Thielen C...de Leval L	18395252	2008
48	Liver X receptor agonists increase airway reactivity in a model of asthma via increasing airway smooth muscle growth. ⁵³ ⁶²	Birrell MA...Belvisi MG	18768884	2008
49	CD4+CD25+ regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling. ⁵³ ⁶²	Kearley J...Lloyd CM	18672278	2008
50	Treatment with anti-CC chemokine receptor 3 monoclonal antibody or dexamethasone inhibits the migration and differentiation of bone marrow CD34 progenitor cells in an allergic mouse model. ⁵³ ⁶²	Ben S...Shen H	18699933	2008

Sources

Genes for Hypereosinophilic Syndrome

Genes related to Hypereosinophilic Syndrome (0 elite genes):

(show all 43)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	FIP1L1	Factor Interacting With PAPOLA And CPSF1	Protein Coding	57.98	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries (show sections)	12676775 17634706 17666373 (more) 15951264 16768284
2	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	Protein Coding	56.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries (show sections)	20010473 16781490 20309429 (more) 15995324 19761433 15036941 15239393 12676775 15667033 12842979 16418325 17634706 16965435 17666373 17940488 19210352 16610578 17549478 15951264 14630792 19013640 19671059 16768284
3	JAK2	Janus Kinase 2	Protein Coding	43.23	Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18843283 12708906
4	IL5	Interleukin 5	Protein Coding	40.15	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8608231 1753511 8906227 (more) 16418325 8238799 17940488 7523745 8601370 8755934 16582580 8425573 20110057 11306981 14699394 8027491 9802371 10511609 15951288 7613117 8294877 9990366 10802841 17160990 2373861 17176889 11148473 15794184 7534262 15947325 9802369 19184361 2193099 14581138 8664444 16342902 2090253 12581193 18395252 1544392 1316789 1334944 7627633 11292021 2230651 8724013 8364199 8493995 1884020 17996260 15534922 8627086 8092143 1918387 2182734 19478474 11505529 10886144 9445301 8665147 1350292 2094320 8346714 1378078 7630699 11927273 10518827 7727874 2206996 10410362 8842549 10887335 9798664 8534765 7573007 7964167 1395793 1732010 18475660 11579103 11350304 9352584 9013977 7549513 11972613 8708148 18829681 12789240 11776778 8887574 2206537 1626792 8391887 8533314 10886718 10377177 10354088 9883292 9455873 9449505 9284977 10036642 8922493 8688671 7499683 7613159 7773153 7718986 7835952 1340036 8419478 2403816 9680139 9698919 9072996 8867725 15889250 15985813 12496441 12459540
5	RNASE3	Ribonuclease A Family Member 3	Protein Coding	34.47	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8364205 9785914 16340277 (more) 14533663 9130522 8744107 16889281 16951266 9501680 2217619 1747458 10354088 12924523 16733488 10698466 1519835 1845343 19034473 18070017 17356298 15935609 10051251 10836317 10830191 10390416 10231326 9025985 16709536 16010632 10456969 9445301 8757629 15358574 11834641 10982220 10611555 9515598 7525344 16358841 16406018 10852530 10942140 10383595 9574886 9452886 8297267 1847158 19055065 10619791 11398366 15248854 8238800 14647858 11703226 9932643 9032180
6	CCL11	C-C Motif Chemokine Ligand 11	Protein Coding	34.02	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14576680 10052481 10782526 (more) 12853519 14629326 14768039 9698931 15916812 8597956 10886144 7869037 18071017 10691892 11316663 11444199 9653092 11346176 10415058 20459697 20227754 17597386 17940487 15753898 11401892 10494838 17620002 12391249 9034156 19864487 14725564 12915771 10491000 10351942 18409371 15947479 14616128 10708591 9637348 12916705 12200110 12193745 11523058 10867510 10516663 8784786 19386785 18768884 18397958 18395252 17305518 16839409 16792175 15767025 15144475 15115860 18214283 11398366 11097314 10360975 11149914 11292021 12737295
7	PRG2	Proteoglycan 2, Pro Eosinophil Major Basic Protein	Protein Coding	32.8	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8043431 14988154 7669668 (more) 2217619 19139036 8757629 7543541 9130522
8	PDGFRB	Platelet Derived Growth Factor Receptor Beta	Protein Coding	32.58	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	20309429 16343267 19175693 (more) 12181402 19761433 19806146 15239393 20053713 12907457 15667033 20164181 18706197
9	EPX	Eosinophil Peroxidase	Protein Coding	32.5	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9785914 7534262 2217619 (more) 1847158 11169280
10	FGFR1	Fibroblast Growth Factor Receptor 1	Protein Coding	29.72	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	20309429 11919391 18566537 (more) 18295660 19761433 19806146 20053713 16781488 18706197
11	ZBTB20	Zinc Finger And BTB Domain Containing 20	Protein Coding	25	Likely pathogenic ⁵
12	IL2RA	Interleukin 2 Receptor Subunit Alpha	Protein Coding	24.55	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1297479 8601370 1726707 (more) 18365140 9472806 8238800 16817798 8448682 11408770 12486319 8857112
13	IL3	Interleukin 3	Protein Coding	23.83	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8485042 8364199 8335853 (more) 9990366 7573007 2206537 1646045 11153599 8509580 8667590 7630699 1375105 8401260 1449809 2065275 12708906 1558975 1350292 1829892 2210871 2193099 7741103 2017199 18409371 7543541 1560199 18214283 10808316 1316789
14	IGHE	Immunoglobulin Heavy Constant Epsilon	Protein Coding	23.59	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10984372 11139663 16340277 (more) 10340953 2317085 2212412 10051274 18060095 7964167 1845343 7798546 10982220 11117270 10795651 11295660 1918403 18396776 17266055 1928948 10951888 11338283 18628641 9704296 17638784 11881503 8894441 8867725 8665387 19900723 8348067 2084865 17426890 15206550 15542945 9866981 8682435 7814459 16050467 12041606 10982224 18325032 10329852 9258771 8993177 11011754 8123579 2244060 1831617 8328717 8011808 7777907 11692702 16487554 16579199 15577824 15172898 14739648 14739774 12588369 15463812 11926586 9692312 9629547 10909631 9369436 9022330 8923129 8283139 8255027 8335848 7794088 7807023 8046328 8114916 8275769 8492455 1563501 20490271 12773262 18387519 16476192 16176405 15935609 15964782 15663557 15301307 11181646 10412634 18552413 10352311 10088027 9589022 9351592 9111874 8887045 8565306 8551692 8414823 19813686 18528638 19766085
15	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	23.05	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18808562 18706197
16	CSF2	Colony Stimulating Factor 2	Protein Coding	21.68	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12950242 7920026 8534765 (more) 8485042 10802841 1646045 8627086 17198080 8364199 17178706 10331501 2012068 9798664 1520621 1885766 16917551 8335853 11245631 7630699 11153599 1540871 9155837 1316789 8450613
17	IGES	Immunoglobulin E Concentration, Serum	Genetic Locus	21.62	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11143821 18246382 12205289 (more) 19195268 11011754 1563501 10743766 19468829 11919392 16720555 18066701 16933010 12702512 12749805 11844130 17425383 7964167 19786854 19620037 12170098 12897312 12485317 16382704 9351592 1687066 18352792
18	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	20.2	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10779297 9230233 10069878 (more) 10444253 18071017 15935609 17940487 8492441 7840216 19596142 11802063
19	IFNA1	Interferon Alpha 1	Protein Coding	20.18	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8630398 8479090 7613117 (more) 8910767 8567949
20	ABL1	ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase	Protein Coding	20.15	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18706197
21	CCL17	C-C Motif Chemokine Ligand 17	Protein Coding	19.51	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18395252
22	MPO	Myeloperoxidase	Protein Coding	19.47	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12924523 1848489 1847158 (more) 7920015 9025985
23	IL13	Interleukin 13	Protein Coding	18.67	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12007717 10069878 11292021 (more) 15032597 17481712 18355911 19471606 10494838 19099351 12642820 11429321 20358028 19811306 19300283 16354949 16120093 14635046 10229862 18672278 16210908 14564354 11823536 11197307 19839977 16266385 12225257 19386785 12391249 11501888 19822647 17561245 16645178 19483109 18502398 18404997 19449446 10934105 11398366
24	IL4	Interleukin 4	Protein Coding	18.29	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11776778 12789240 14768039 (more) 10592468 17996260 12007717 1350292 7964167 8121089 8228575 9307252 9816049 10886718 19449446 1704262 9761759 11436359 11306960 9680139 8867725 8724013 7560666 19471606 17198080 15979827 12459540 11994714 11429321 10605015 9861741 9352584 8100845 19811306 19300283 11496235 11781348 10606935 7897199 7927488 8130650 2182734 19386785 14992689 12244197 16849489 16210908 11823536 11435248 10887335 8799728 20139223 19839977 18804852 15209953 11117270 11080735 10679107 9407718 7521206 1829892 19552640 15889128 11122208 10421818 10229862 9683547 7523745 1560199 19099351 15935609 11398366 7734977 20486329 11727517 12592561 11292021 9455873
25	ALOX5	Arachidonate 5-Lipoxygenase	Protein Coding	16.93	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1659282
26	IFNA2	Interferon Alpha 2	Protein Coding	16.85	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9072488 10741923 17868861 (more) 11455154
27	CCL24	C-C Motif Chemokine Ligand 24	Protein Coding	16.44	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15805998 15947325 10415058 (more) 10491000 19552640 12193745
28	CCL26	C-C Motif Chemokine Ligand 26	Protein Coding	15.76	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15947325 15805998 17073866 (more) 18397958 19811306 18073124
29	IL5RA	Interleukin 5 Receptor Subunit Alpha	Protein Coding	15.49	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17914408 7577627 12759409
30	PLA2G4A	Phospholipase A2 Group IVA	Protein Coding	15.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9987681
31	CCR3	C-C Motif Chemokine Receptor 3	Protein Coding	15.43	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17983872 14698143 18699933 (more) 10708591 10570327
32	CCL5	C-C Motif Chemokine Ligand 5	Protein Coding	14.84	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12853519 15794069 12388374 (more) 11398366 11496242 17597386 17620002 9032215 15947479 11523058 20459697 17305518 18395252 10491000 10942140
33	IL2	Interleukin 2	Protein Coding	14.81	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	2206537 1884020 8346714 (more) 2273659 15889250 2094320 1477320 10508829 8121089 2094321 1560693 1511459 8381564 8206677 1456395 8731847 8532404 8044833 8386711 2206996 11496242 11306960 10370677 7629429 10887335 9432015 1618895 2072602 19839977 8666429 8233281 2373861 10824075 9861741 9452886 8131526 8412115 8320888 1485586 17198080 8533314 15690709 17085290 8857112 8888813 11418300
34	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	14.39	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
35	IL9	Interleukin 9	Protein Coding	14.17	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10427975 18404997 10979962 (more) 19449446 11781348 15294996 15007348 12225257 10329852 19471606 19099351
36	IFNG	Interferon Gamma	Protein Coding	14.14	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10544202 9680139 11994714 (more) 8206677 9305229 20486329 7734977 15641637 16449531 10508829 18804852 7897199 7964167 8130650 17426890 15639296 1350292 2210871 8758312 16849489 16838642 11120841 10592468 11398366 11418300 12007717 9355792
37	JAK1	Janus Kinase 1	Protein Coding	13.85	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
38	STAT5B	Signal Transducer And Activator Of Transcription 5B	Protein Coding	13.77	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
39	IL10	Interleukin 10	Protein Coding	12.85	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18485518 11295668 11080710 (more) 11196547 19912977 18691071 17940487
40	JUN	Jun Proto-Oncogene, AP-1 Transcription Factor Subunit	Protein Coding	12.84	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
41	CD69	CD69 Molecule	Protein Coding	12.81	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8813097 11408770
42	ANPEP	Alanyl Aminopeptidase, Membrane	Protein Coding	12.77	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
43	MYH11	Myosin Heavy Chain 11	Protein Coding	12.39	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17452259 9713991 8779782

Sources

Variations for Hypereosinophilic Syndrome

ClinVar genetic disease variations for Hypereosinophilic Syndrome:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	JAK2, ZBTB20	t(3;9)(q13.31;p24.1)	TRANS	Likely Pathogenic	869413		GRCh37: 3:114069121-114069122 GRCh38:

Sources

Expression for Hypereosinophilic Syndrome

Search GEO for disease gene expression data for Hypereosinophilic Syndrome.

Sources

Pathways for Hypereosinophilic Syndrome

Pathways related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 53)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.95	ABL1 CCL11 CSF2 CXCL8 EPX IFNA1
2	Signal Transduction ⁶⁶	13.73	PDGFRB PDGFRA KIT JAK2 IL5 IL3
3	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.61	PRG2 PDGFRB PDGFRA KIT JAK2 IL5
4	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.52	CCL11 CSF2 CXCL8 FGFR1 IFNA1 IL2RA
5	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.47	PDGFRB PDGFRA KIT JAK2 IL5 IL3
6	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.31	JAK2 IL5 IL3 IL2RA IFNA1 CXCL8
7	RAF/MAP kinase cascade ⁶⁶ Show member pathways Diseases of signal transduction by growth factor receptors and second messengers ⁶⁶ MAPK family signaling cascades ⁶⁶ MAPK1/MAPK3 signaling ⁶⁶	13.3	PDGFRB PDGFRA KIT JAK2 IL5 IL3
8	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.14	CCL11 CSF2 CXCL8 FGFR1 IL2RA IL3
9	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	13.06	PRG2 PDGFRB PDGFRA KIT IL3 IL2RA
10	p70S6K Signaling ⁶⁴ Show member pathways mTOR Pathway ⁶⁴ Renin-Angiotensin Pathway ⁶⁴	13.03	PDGFRB PDGFRA KIT JAK2 IL3 IL2RA
11	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	12.96	PDGFRB PDGFRA KIT JAK2 IL5 IL3
12	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.92	FGFR1 IFNA1 IL2RA IL3 JAK2 KIT
13	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.82	PDGFRB PDGFRA KIT JAK2 FGFR1
14	Malignant pleural mesothelioma ⁷⁴	12.68	PDGFRB PDGFRA KIT FGFR1 CSF2
15	NF-kappaB Signaling ³	12.56	KIT JAK2 IL3 IL2RA IFNA1
16	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.44	PDGFRB PDGFRA KIT FGFR1
17	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.44	FGFR1 IL2RA IL5 PDGFRA PDGFRB
18	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.37	PDGFRB PDGFRA KIT IL3 FGFR1
19	Interleukin-2 family signaling ⁶⁶ Show member pathways Interleukin receptor SHC signaling ⁶⁶ Interleukin-15 signaling ⁶⁶ Interleukin-21 signaling ⁶⁶ Interleukin-3, Interleukin-5 and GM-CSF signaling ⁶⁶ Regulation of signaling by CBL ⁶⁶ Signaling by CSF1 (M-CSF) in myeloid cells ⁶⁶	12.28	JAK2 IL5 IL3 IL2RA CSF2
20	Ras signaling ⁷⁴	12.24	ABL1 FGFR1 KIT PDGFRA PDGFRB
21	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.19	PDGFRB PDGFRA IL2RA FGFR1
22	Tyrosine Kinases / Adaptors ³	12.02	PDGFRB PDGFRA KIT JAK2 FGFR1 ABL1
23	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.99	KIT IL5 IL3 IL2RA CSF2
24	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.92	JAK2 CXCL8 CCL11
25	Allograft rejection ⁷⁴	11.88	PDGFRA IL5 IL2RA CXCL8
26	Immune response IL-2 activation and signaling pathway ²² Show member pathways IL-2 signaling pathway ⁷⁴ Immune response IL-3 activation and signaling pathway ²²	11.87	IL2RA IL3 JAK2
27	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	11.87	PDGFRB PDGFRA KIT JAK2 IL5 IL3
28	Hippo-Merlin signaling dysregulation ⁷⁴ Show member pathways Hippo signaling regulation pathways ⁷⁴	11.86	PDGFRB PDGFRA KIT FGFR1
29	Cytokine production by Th17 cells in CF (Mouse model) ²² Show member pathways Cytokine production by Th17 cells in CF ²²	11.85	JAK2 CXCL8 CSF2
30	Angiogenesis (CST) ³	11.83	PDGFRB PDGFRA FGFR1
31	Innate Lymphoid Cells Differentiation ⁶⁵	11.77	KIT IL5 IL2RA
32	VEGF Pathway (Tocris) ⁷⁰ Show member pathways Sorafenib Pharmacodynamics ⁶⁰	11.76	FGFR1 KIT PDGFRB
33	Glucocorticoid receptor regulatory network ⁶¹	11.75	IL5 CXCL8 CSF2
34	Burn wound healing ⁷⁴	11.74	PDGFRB FGFR1 CXCL8
35	IL3-mediated signaling events ⁶¹ Show member pathways GMCSF-mediated signaling events ⁶¹ IL5-mediated signaling events ⁶¹	11.73	JAK2 IL5 IL3 CSF2
36	G-protein signaling_RhoA regulation pathway ²²	11.7	PDGFRB PDGFRA IL3 FGFR1
37	AP-1 transcription factor network ⁶¹	11.69	IL5 CXCL8 CSF2
38	Ponatinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Show member pathways Aripiprazole Pathway, Pharmacokinetics ⁶⁰ Bosutinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Imatinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ In progress: Docetaxel Pathway, Pharmacokinetics ⁶⁰ Nilotinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Taxane Pathway, Pharmacokinetics ⁶⁰	11.67	PDGFRB PDGFRA KIT ABL1
39	Lung fibrosis ⁷⁴	11.66	IL5 CXCL8 CSF2 CCL11
40	IL4-mediated signaling events ⁶¹	11.63	JAK2 IL5 CCL11
41	Calcineurin-regulated NFAT-dependent transcription in lymphocytes ⁶¹ Show member pathways Calcium signaling in the CD4+ TCR pathway ⁶¹	11.63	IL5 IL3 IL2RA CXCL8 CSF2
42	SHP2 signaling ⁶¹	11.58	PDGFRB JAK2 IL2RA
43	Th2 Differentiation ⁶⁵	11.51	JAK2 IL5 IL2RA CCL11
44	Signaling events mediated by PTP1B ⁶¹	11.5	PDGFRB JAK2 ABL1
45	Alzheimers Disease Pathway ⁶⁴	11.49	PDGFRB PDGFRA FGFR1
46	Vemurafenib Pathway, Pharmacodynamics ⁶⁰	11.46	FGFR1 PDGFRA PDGFRB
47	Pazopanib Pathway, Pharmacokinetics ⁶⁰ Show member pathways Sunitinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	11.35	PDGFRB PDGFRA KIT
48	Cytokines and inflammatory response ⁷⁴	11.28	IL5 IL3 CSF2
49	Immune infiltration in pancreatic cancer ⁷⁴	11.25	IL5 CXCL8 CSF2
50	Imatinib and chronic myeloid leukemia ⁷⁴	11.06	PDGFRB PDGFRA KIT ABL1

Sources

GO Terms for Hypereosinophilic Syndrome

Cellular components related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	10.16	RNASE3 KIT IL5 IL3 IGHE IFNA1
2	extracellular region	GO:0005576	10	CCL11 CSF2 CXCL8 EPX FGFR1 IFNA1
3	granulocyte macrophage colony-stimulating factor receptor complex	GO:0030526	8.92	JAK2 CSF2

Biological processes related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show all 31)

#	Name	GO ID	Score	Top Affiliating Genes
1	protein phosphorylation	GO:0006468	10.25	ABL1 CCL11 CSF2 FGFR1 JAK2 KIT
2	cytokine-mediated signaling pathway	GO:0019221	10.24	KIT JAK2 IL5 IFNA1
3	positive regulation of cell migration	GO:0030335	10.23	PDGFRB PDGFRA KIT JAK2 CSF2 CCL11
4	transmembrane receptor protein tyrosine kinase signaling pathway	GO:0007169	10.22	PDGFRB PDGFRA KIT FGFR1
5	positive regulation of cell population proliferation	GO:0008284	10.22	PDGFRB PDGFRA KIT JAK2 IL5 IL3
6	positive regulation of peptidyl-tyrosine phosphorylation	GO:0050731	10.15	ABL1 IL3 IL5 JAK2
7	protein autophosphorylation	GO:0046777	10.15	ABL1 FGFR1 JAK2 KIT PDGFRA PDGFRB
8	positive regulation of kinase activity	GO:0033674	10.14	PDGFRB PDGFRA KIT FGFR1
9	positive regulation of fibroblast proliferation	GO:0048146	10.12	PDGFRB PDGFRA ABL1
10	positive regulation of MAPK cascade	GO:0043410	10.11	PDGFRB PDGFRA KIT JAK2 FGFR1
11	phosphatidylinositol-mediated signaling	GO:0048015	10.1	FGFR1 PDGFRA PDGFRB
12	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	10.1	CSF2 IL3 JAK2 KIT
13	positive regulation of receptor signaling pathway via JAK-STAT	GO:0046427	10.09	KIT JAK2 IL5
14	chemotaxis	GO:0006935	10.08	RNASE3 PDGFRB PDGFRA CXCL8 CCL11
15	phosphorylation	GO:0016310	10.07	ABL1 FGFR1 JAK2 KIT PDGFRA PDGFRB
16	positive regulation of phosphatidylinositol 3-kinase activity	GO:0043552	10.06	PDGFRB PDGFRA KIT
17	immune response	GO:0006955	10.06	CCL11 CSF2 CXCL8 IGHE IL2RA IL3
18	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	9.96	PDGFRB PDGFRA KIT JAK2 FGFR1
19	response to fluid shear stress	GO:0034405	9.95	PDGFRB CSF2
20	positive regulation of leukocyte proliferation	GO:0070665	9.93	JAK2 CSF2
21	platelet-derived growth factor receptor-beta signaling pathway	GO:0035791	9.92	PDGFRB ABL1
22	granulocyte-macrophage colony-stimulating factor signaling pathway	GO:0038157	9.91	JAK2 CSF2
23	mast cell chemotaxis	GO:0002551	9.9	KIT CCL11
24	metanephric glomerular capillary formation	GO:0072277	9.88	PDGFRB PDGFRA
25	positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway	GO:0038091	9.87	PDGFRB PDGFRA
26	platelet-derived growth factor receptor signaling pathway	GO:0048008	9.87	PDGFRB PDGFRA JAK2 ABL1
27	defense response to nematode	GO:0002215	9.86	PRG2 EPX
28	multicellular organism development	GO:0007275	9.83	PDGFRB PDGFRA KIT FGFR1
29	positive regulation of protein modification process	GO:0031401	9.64	PDGFRB KIT
30	positive regulation of phospholipase C activity	GO:0010863	9.56	PDGFRB PDGFRA KIT FGFR1
31	peptidyl-tyrosine phosphorylation	GO:0018108	9.47	PDGFRB PDGFRA KIT JAK2 IL5 FGFR1

Molecular functions related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein kinase activity	GO:0004672	9.91	PDGFRB PDGFRA KIT JAK2 FGFR1 ABL1
2	SH2 domain binding	GO:0042169	9.88	KIT JAK2 ABL1
3	kinase activity	GO:0016301	9.87	PDGFRB PDGFRA KIT JAK2 FGFR1 ABL1
4	transmembrane receptor protein tyrosine kinase activity	GO:0004714	9.76	FGFR1 KIT PDGFRA PDGFRB
5	vascular endothelial growth factor binding	GO:0038085	9.67	PDGFRB PDGFRA
6	cytokine activity	GO:0005125	9.65	IL5 IL3 IFNA1 CXCL8 CSF2 CCL11
7	protein tyrosine kinase activity	GO:0004713	9.36	PDGFRB PDGFRA KIT JAK2 FGFR1 ABL1